Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation
Authors
Keywords
-
Journal
CELL DEATH AND DIFFERENTIATION
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-03-01
DOI
10.1038/s41418-019-0310-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Convergence-Based Framework for Cancer Drug Resistance
- (2018) David J. Konieczkowski et al. CANCER CELL
- Toward Minimal Residual Disease-Directed Therapy in Melanoma
- (2018) Florian Rambow et al. CELL
- Tumor elastography and its association with collagen and the tumor microenvironment.
- (2018) Johannes Riegler et al. CLINICAL CANCER RESEARCH
- Integrating single-cell transcriptomic data across different conditions, technologies, and species
- (2018) Andrew Butler et al. NATURE BIOTECHNOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing
- (2018) Zsofia Miskolczi et al. ONCOGENE
- Krasmutant genetically engineered mouse models of human cancers are genomically heterogeneous
- (2017) Wei-Jen Chung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma
- (2017) Lawrence N. Kwong et al. Cell Reports
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
- (2017) A. Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
- (2017) Mark Merchant et al. PLoS One
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
- (2015) Eishu Hirata et al. CANCER CELL
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
- (2015) Douglas B. Johnson et al. EUROPEAN JOURNAL OF CANCER
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment
- (2013) V. T. Phan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
- (2012) Christopher T. Saunders et al. BIOINFORMATICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data
- (2011) Valentina Boeva et al. BIOINFORMATICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generation of melanocytes from neural crest cells
- (2011) Lukas Sommer Pigment Cell & Melanoma Research
- Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
- (2010) William McLaren et al. BIOINFORMATICS
- Fast and SNP-tolerant detection of complex variants and splicing in short reads
- (2010) T. D. Wu et al. BIOINFORMATICS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
- (2009) Linda Madisen et al. NATURE NEUROSCIENCE
- The making of a melanocyte: the specification of melanoblasts from the neural crest
- (2008) Aaron J. Thomas et al. Pigment Cell & Melanoma Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now